REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
==== Syrian Arab Republics ==== In 2013, Damascus University instituted a Master's program in Medical Physics, which has significantly contributed to the training of numerous medical physicists across various university and local hospitals, as well as several universities within the Syrian Arab Republic. This program has facilitated the dissemination of knowledge through the publication of several external research articles addressing the role of medical physicists in oncology. Furthermore, it has resulted in the production of multiple academic textbooks in the field of medical physics.
Ideally, the rods are hyperbolic, however cylindrical rods with a specific ratio of rod diameter-to-spacing provide an easier-to-manufacture adequate approximation to hyperbolas. Small variations in the ratio have large effects on resolution and peak shape. Different manufacturers choose slightly different ratios to fine-tune operating characteristics in context of anticipated application requirements. Since the 1980s, the MAT company and subsequently Finnigan Instrument Corporation used hyperbolic rods produced with a mechanical tolerance of 0.001 mm, whose exact production process was a well-kept secret within the company.
=== Parmalat scandal === In January 2004, Italian dairy giant Parmalat was caught in a multibillion-euro accounting scandal, culminating in the arrest of the owner Calisto Tanzi. Parmalat CFO Fausto Tonna told the Italian business daily Il Sole 24 Ore that Tetra Pak had made substantial payments to Tanzi and his family and to a company in the Cayman Islands belonging to Parmalat. Tetra Pak acknowledged having made payments to Parmalat but stated that the payments had been made as discounts to subsidize marketing operations and pricing, as is usual practice with large customers. Tetra Pak was asked by Italian authorities to provide documentation on the transactions, and found that payments had been made since 1995 as part of regular operations but that no payments had been made specifically to the Tanzi family. Calisto Tanzi was eventually sentenced to eight years imprisonment for fraud by the Italian high court in Milan after several appeals in lower courts.
=== Common ingredients === The final type of ingredients available to campers are those that are typically found in the grocery store. Some examples of these types of food are polenta, grits, quick-cooking pasta (such as angel hair pasta), ramen, instant potatoes, dried soups, jerky and pouch meats such as tuna, Spam or salmon. When using these common ingredients, campers often repackage them to reduce packaging or combine them into a meal-ready package, therefore reducing prep time at camp. The main requirement that campers look for in these types of ingredients is the cooking time with 20 minutes being the longest amount of cook time that most campers will tolerate.
Sources: en.wikipedia.org
=== Outside Greece === Although frappés are commonly associated with Greece, their popularity has grown in other nations in the recent years. Frappés first became broadly known outside of Greece during the 2004 Summer Olympics in Athens, wherein many tourists became fond of them and an article was published in the Los Angeles Times. Immigrants and tourists in Greece have also helped to take the frappé abroad.
== External links == Procter and Gamble web page for Intrinsa. Information on Intrinsa and User Forum Patch 'to boost female sex drive' FDA Looks at P&G's Sex-Drive Drug Women's sexual health deserves equal attention
== Function == The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins. It regulates gene expression, morphogenesis, and differentiation and it also plays a role in cell cycle progression, particularly at S-phase. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined, and the p200 isoform of Cux1 is processed proteolytically to smaller active isoforms, such as p110. Cux1 DNA binding is stimulated by activation of the PAR2/F2RL1 cell-surface G-protein-coupled receptor in fibroblasts and breast-cancer epithelial cells to regulate Matrix metalloproteinase 10, Interleukin1-alpha, and Cyclo-oxygenase 2 (COX2) genes. Multiple reviews have detailed the tissue-specific functions and genetic interactions in Drosophila and the early characterization of the CDP in mammalian cells, expression and activity of CUX1 in the myeloid cell lineage, multiple CUX1 isoforms, modes of DNA binding, early mouse models and cell-based assays, roles of CUX1 in kidney development and homeostasis, mechanisms by which CUX1 stimulates cell migration and invasion, roles of CUX1 and CUX2 in neurons of the cortex upper layer and the paradoxical implications of CUX1 in cancer. In addition, a number of commentaries present more specific views and speculations.
== Career == Somogyi was born on March 7, 1883, in the village of Zsámánd in Hungary (today Reinersdorf, part of Heiligenbrunn, Austria). He graduated in chemical engineering from the University of Budapest in 1905. After an additional year as an assistant in biochemistry, Somogyi went to the United States, where he eventually found a position as an assistant in biochemistry at Cornell University (1906–1908). He returned to Budapest where he worked at the Municipal Laboratory for the next decade. In 1914, he received his Ph.D. from the University of Budapest, submitting a dissertation on catalytic hydrogenation. During World War I he was in charge of providing food to the destitute. Somogyi was invited to return to the United States by Philip A. Shaffer, whom he had known at Cornell. In 1922 Somogyi became an instructor in biochemistry at Washington University School of Medicine. There Somogyi worked with Shaffer and Edward Adelbert Doisy on insulin preparation and insulin's use in the treatment of diabetes. In 1926, Somogyi became the first biochemist on the staff of the new Jewish Hospital of St. Louis where he worked closely with physicians. He directed the hospital's clinical laboratory until he retired in 1957.
==== Other tests ==== A radiological procedure known as a sialogram is available as a reliable and accurate test for Sjögren's disease. A contrast agent is injected into the parotid duct, which opens from the cheek into the vestibule of the mouth opposite the neck of the upper second molar tooth. The test is intended to detect any blockage in the salivary gland ducts (i.e., parotid duct) and the amount of saliva that flows into the mouth. For Sjögren's disease, sudomotor function through electrochemical skin conductance may help in the diagnosis process.
Sources: en.wikipedia.org
The small vessels in the skin affected are located in the superficial dermis and include arterioles (small arteries carrying blood to capillaries), capillaries, and venules (small veins receiving blood from capillaries). In general, immune complexes deposit in vessel walls leading to activation of the complement system. C3a and C5a, proteins produced from the complement system, attract neutrophils to the vessels. Once activated, neutrophils then release preformed substances, including enzymes, causing damage to vessel tissue. Evidence of this process can be seen with a sample of removed skin tissue, or biopsy, viewed under a microscope. Neutrophils are seen surrounding blood vessels and their debris within vessel walls, causing fibrinoid necrosis. This finding on histological examination is termed "leukocytoclastic vasculitis". Considering the wide range of potential causes leading to cutaneous small vessel vasculitis, there are subtle variations in the underlying pathophysiology for each cause. For example, medications are metabolized to smaller molecules that can attach to proteins in the blood or vessel walls. The immune system senses these altered proteins as foreign and produces antibodies in efforts to eliminate them from the body. A similar process occurs with infectious agents, such as bacteria, in which antibodies target microbial components.
== mRNA == Messenger RNA (mRNA) is a single-stranded RNA molecule that is complementary to one of the DNA strands of a gene. An mRNA molecule transfers a portion of the DNA code to other parts of the cell for making proteins. DNA therapeutics needs access to the nucleus to be transcribed into RNA, and its functionality depends on nuclear envelope breakdown during cell division. However, mRNA therapeutics do not need to enter into the nucleus to be functional since it will be translated immediately once it has reached to the cytoplasm. Moreover, unlike plasmids and viral vectors, mRNAs do not integrate into the genome and therefore do not have the risk of insertional mutagenesis, making them suitable for use in cancer vaccines, tumor immunotherapy and infectious disease prevention.
Although they disliked each other as children, she and Erasmas become romantically involved in the course of the story. Jad: A Millenarian fraa from the Concent of Saunt Edhar. Jad is summoned to the Convox at the same time of Erasmas, but tells Erasmas to look for Orolo instead of traveling directly to the Convox. Jad is a participant in philosophical discussions at the Convox and plays a key role in the mission to the alien ship. It is hinted that he is hundreds of years old and possesses the ability to be conscious within multiple parallel universes. Cord: Erasmas' half-sister and a machinesmith who lives near the Concent of Saunt Edhar. She accompanies Erasmas on his search for Orolo. She and Yul become romantically involved in the course of the story. Sammann: A member of a social caste of computer experts from the Concent of Saunt Edhar who accompanies Erasmas on his search for Orolo. He provides technological support and knowledge for Erasmas' companions throughout the story. Yulassetar Crade (nickname "Yul"): A wilderness guide who joins the expedition to find Orolo. He and Cord become romantically involved in the course of the story. Ganelial Crade (nickname "Gnel"): A religious man who volunteers to drive the avout to the Convox, before joining the search for Orolo. Erasmas mistrusts Gnel at first, but becomes friends over the course of the story. Jules Verne Durand: A linguist from Laterre who infiltrates the Convox to gather information for the aliens. He defects to the Arbrans and joins the mission to the alien ship.
Even before the partitions from the late 18th century, the Russian Empire had already acquired some territories of the Polish–Lithuanian Commonwealth (a real union of Kingdom of Poland with the Grand Duchy of Lithuania). The first Russian partition took place in the late 17th century when the forced Treaty of Andrusovo signed in 1667 granted Russia the Commonwealth's territory in the Eastern Ukraine. Under the Third Partition of Poland Russia acquired Courland, all Lithuanian territory east of the Nieman River, and the remaining parts of Volhynian Ukraine.
== History == Two papers appearing in 1994 anticipated the deeper understanding of innate immune reactivity, pointing towards the subsequent understanding of the nature of the adaptive immune response. The first came from transplant surgeons who conducted a prospective randomized, double-blind, placebo-controlled trial. Administration of recombinant human superoxide dismutase (rh-SOD) in recipients of cadaveric renal allografts demonstrated prolonged patient and graft survival with improvement in both acute and chronic rejection events. They speculated that the effect was related to SOD's antioxidant action on the initial ischemia/reperfusion injury of the renal allograft, thereby reducing the immunogenicity of the allograft. Thus, free radical-mediated reperfusion injury was seen to contribute to the process of innate and subsequent adaptive immune responses. The second study suggested the possibility that the immune system detected "danger", through a series of what is now called damage-associated molecular pattern molecules (DAMPs), working in concert with both positive and negative signals derived from other tissues. Thus, these papers anticipated the modern sense of the role of DAMPs and redox, important, apparently, for both plant and animal resistance to pathogens and the response to cellular injury or damage. Although many immunologists had earlier noted that various "danger signals" could initiate innate immune responses, the "DAMP" was first described by Seong and Matzinger in 2004.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.